Whitehawk Therapeutics Stock Rockets on AI Partnership – What Investors Need to Know
Whitehawk’s stock popped dramatically on Oct. 16 after news of the Tempus collaboration. Shares had been around $2 per share in mid-Octoberstockinvest.us, but the new AI partnership sent them soaring in early trading. By mid-day Oct. 16, various data sites showed WHWK up roughly 50–67% on the sessioninvesting.com. The sudden jump reflects investor excitement about the Tempus deal, which was announced in a press release on Oct. 16marketscreener.com. The Tempus AI collaboration was officially billed as a “multi-year” partnership to use Tempus’s de-identified, multimodal clinical data to improve Whitehawk’s ADC drug developmentmarketscreener.com. In practice, this means Whitehawk will apply Tempus’s large real-world patient database and AI analytics to design smarter clinical trials and identify the patients most likely to benefit from its ADCsmarketscreener.combusinesswire.com. Tempus’s COO, Ryan Fukushima, said that pairing “Tempus’ comprehensive, multimodal data” with Whitehawk’s ADC expertise creates “a powerful foundation” for validating Whitehawk’s cancer targetsmarketscreener.com. Whitehawk’s CEO, Dr. Dave Lennon, added that the goal is to “better understand the expression of our ADC protein targets” using data-driven insights to prioritize which cancers to target firstmarketscreener.com. In other words, instead of relying solely on lab tests of tumor samples, the partnership will use large-scale RNA and clinical data to
